Abstract:BACKGROUND:Cancer stem cells (CSCs) are characterized by their ability to self-renew, to differentiate into multiple cell types and also drive tumor formation, altogether making them important cellular targets for therapeutic intervention. However, existing CSC-targeting drugs do not significantly improve clinical outcomes. More recently, preclinical studies of natural product-derived compounds have demonstrated their potential usefulness as a therapeutic cancer treatment through their cytotoxic actions on CSCs.PURPOSE:Here, we identify CSC-specific compounds derived from natural products and characterize their putative mechanisms of action in CSCs.METHODS:Glioblastoma stem cells (GSCs) were labeled with EGFP via homologous recombination and utilized for a high-throughput screen of 8,344 fractions from 386 herbal medicines. The fractions that extinguished EGFP fluorescence signal were then further characterized by LC-MS/MS. Next, several putative cytotoxic compounds were evaluated for their cytotoxic effects on GSCs, cancer cell lines and immortalized cells using a variety of methods to study cell proliferation (EdU incorporation assay), cell death (cleaved-Caspase-3 immunostaining), DNA damage (comet assay), mitochondrial membrane changes (JC-1 immunostaining), and tumor formation in vitro (soft agar colony forming assay). We also performed surface plasmon resonance analysis, western blotting, and immunohistochemistry to characterize the putative mechanisms underlying the cytotoxic effects of putative compounds on GSCs. Finally, we carried out xenograft tumor growth assays to study the cytotoxic potential of several candidates in vivo.RESULTS:Our high throughput screen led to the identification of the furostanol saponin taccaoside A and its two homologs from the rhizomatous geophyte Tacca. subflabellata that were cytotoxic to GSCs. Interestingly, the cytotoxic effect of taccaoside A on cell lines was significantly less compared to its homologs, owing to stereochemical differences of a carbon-carbon double bond between C-20 and C-22. Molecular studies revealed that taccaoside A binds to RAS to inhibit downstream effector signaling. Correspondingly, blockade of the interaction between taccaoside A and RAS abolished the inhibitory effect of this compound on CSCs. Furthermore, taccaoside A treatment was effective in limiting tumor cell growth in vivo.CONCLUSION:Our study yielded an effective approach to screen for CSC-specific agents. Through this approach, we identified taccaoside A from the rhizomatous geophyte Tacca. subflabellata are cytotoxic to CSCs through a molecular mechanism that involves RAS binding and suppression of its downstream signaling. Our findings indicate taccaoside A is a potential lead compound for anti-CSC drug discovery.

A high-throughput screen identifies inhibitors of lung cancer stem cells

Simplified Synthesis of Renieramycin T Derivatives to Target Cancer Stem Cells Via Β-Catenin Proteasomal Degradation in Human Lung Cancer

Identification of stem-like cells in non-small cell lung cancer cells with specific peptides.

Ribosome Display and Selection of Single‐chain Variable Fragments Effectively Inhibit Growth and Progression of Microspheres in Vitro and in Vivo

Wnt/β-catenin Signaling Pathway in Lung Cancer Stem Cells is a Potential Target for the Development of Novel Anticancer Drugs.

High Throughput-Screening of Native Herbal Compounds Identifies Taccaoside A As a Cytotoxic Compound That Mediates RAS Signaling in Cancer Stem Cells.

Molecular Imaging in Tracking Tumor Stem-Like Cells

Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation.

Can Lung Cancer Stem Cells Be Targeted for Therapies?

Drug Screening Identifies Niclosamide as an Inhibitor of Breast Cancer Stem-Like Cells

A Novel Anticancer Agent SNG1153 Inhibits Growth of Lung Cancer Stem/progenitor Cells

Wnt Signaling Regulates the Stemness of Lung Cancer Stem Cells and Its Inhibitors Exert Anticancer Effect on Lung Cancer SPC-A1 Cells

A Functional Screening Identifies a New Organic Selenium Compound Targeting Cancer Stem Cells: Role of c‐Myc Transcription Activity Inhibition in Liver Cancer

Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.

Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model

Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation

Unveiling potential drug targets for lung squamous cell carcinoma through the integration of druggable genome and genome-wide association data

A Computational Method For The Identification Of Candidate Drugs For Non-Small Cell Lung Cancer

Actinomycin D and Telmisartan Combination Targets Lung Cancer Stem Cells Through the Wnt/Beta Catenin Pathway

Protocol for 3D screening of lung cancer spheroids using natural products

Supplementary Figures S1-S15 from Targeting the C-Met/fzd8 Signaling Axis Eliminates Patient-Derived Cancer Stem–like Cells in Head and Neck Squamous Carcinomas